Advertisement

Molecular Medicine

, Volume 20, Issue 1, pp 456–465 | Cite as

Human Genetic Evidence for Involvement of CD137 in Atherosclerosis

  • Leif Å Söderström
  • Karl Gertow
  • Lasse Folkersen
  • Maria Sabater-Lleal
  • Eva Sundman
  • Yuri Sheikine
  • Anuj Goel
  • Damiano Baldassarre
  • Steve E. Humphries
  • Ulf de Faire
  • Hugh Watkins
  • Elena Tremoli
  • Fabrizio Veglia
  • Anders Hamsten
  • Göran K. Hansson
  • Peder S. Olofsson
Research Article

Abstract

Atherosclerosis is an inflammatory disease and the main cause of cardiovascular disease. Inflammation promotes plaque instability and clinical disease, such as myocardial infarction, stroke and peripheral vascular disease. Subclinical atherosclerosis begins with thickening of the arterial intimal layer, and increased intima-media thickness (IMT) in the carotid artery is a widely used measurement of subclinical atherosclerosis. Activation of CD137 (tumor necrosis factor receptor super family 9) promotes inflammation and disease development in murine atherosclerosis. CD137 is expressed in human atherosclerosis, but its role is largely unknown. This study uses a genetic approach to investigate CD137 in human atherosclerotic disease. In publicly available data on genotype and gene expression from the HapMap project, the minor T allele of rs2453021, a single nucleotide polymorphism in CD137, was significantly associated with CD137 gene expression. In the PROCARDIS and Wellcome Trust Case Control Consortium (WTCCC) cohorts of 13,029 cases and controls, no significant association was detected between the minor T allele of rs2453021 and risk for coronary artery disease or myocardial infarction. However, in the IMPROVE multicenter study of 3,418 individuals, the minor T allele of rs2453021 was associated with increased IMT of the common carotid artery (CCA), as measured by ultrasonography, with presence of plaque in CCA and with increased incidence of adverse noncardiac vascular events. Taken together, this study shows that the minor T allele of rs2453021 is associated with increased IMT in the CCA and increased risk of incident noncardiac vascular events, thus providing the first human genetic evidence for involvement of CD137 in atherosclerosis.

Notes

Acknowledgments

This study was supported by the Swedish Heart-Lung Foundation, the Wenner-Gren Foundation, Karolinska Institutet, Stiftelsen för Gamla Tjänarinnor, the Swedish Research Council (projects 0593, 6816 and 8691 and Linnaeus support 8703), the Swedish Foundation for Strategic Research, the Cardiovascular and Diabetes Programmes of the Karolinska Institutet and Stockholm County Council, the Knut and Alice Wallenberg Foundation and the European Commission (AtheroRemo, PROCARDIS and IMPROVE collaborative projects), the Academy of Finland, the Ministry of Education and Culture of Finland, the City of Kuopio, the British Heart Foundation and the Italian Ministry of Health (Ricerca Corrente). SE Humphries is supported by the British Heart Foundation (PG08/008).

References

  1. 1.
    Hansson GK. (2005) Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352:1685–95.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Hansson GK, Hermansson A. (2011) The immune system in atherosclerosis. Nat. Immunol. 12:204–12.CrossRefGoogle Scholar
  3. 3.
    Legein B, Temmerman L, Biessen EA, Lutgens E. (2013) Inflammation and immune system interactions in atherosclerosis. Cell. Mol. Life Sci. 70:3847–69.CrossRefPubMedGoogle Scholar
  4. 4.
    van den Oord SC, et al. (2013) Carotid intima-media thickness for cardiovascular risk assessment: systematic review and meta-analysis. Atherosclerosis. 228:1–11.CrossRefPubMedGoogle Scholar
  5. 5.
    Tabas I, Williams KJ, Boren J. (2007) Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 116:1832–44.CrossRefPubMedGoogle Scholar
  6. 6.
    Libby P, Ridker PM, Hansson GK. (2011) Progress and challenges in translating the biology of atherosclerosis. Nature. 473:317–25.CrossRefGoogle Scholar
  7. 7.
    Wigren M, et al. (2012) Low levels of circulating CD4+FoxP3+ T cells are associated with an increased risk for development of myocardial infarction but not for stroke. Arterioscler. Thromb. Vasc. Biol. 32:2000–4.CrossRefPubMedGoogle Scholar
  8. 8.
    Klingenberg R, et al. (2013) Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis. J. Clin. Invest. 123:1323–34.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Reardon CA, et al. (2001) Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21:1011–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Zhou X, Nicoletti A, Elhage R, Hansson GK. (2000) Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation. 102:2919–22.CrossRefGoogle Scholar
  11. 11.
    Wang C, Lin GH, McPherson AJ, Watts TH. (2009) Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol. Rev. 229:192–215.CrossRefPubMedGoogle Scholar
  12. 12.
    Watts TH. (2005) TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23:23–68.CrossRefPubMedGoogle Scholar
  13. 13.
    Dumitriu IE, et al. (2012) High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome. Circ. Res. 110:857–69.CrossRefPubMedGoogle Scholar
  14. 14.
    Olofsson PS, et al. (2008) CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation. 117:1292–301.CrossRefPubMedGoogle Scholar
  15. 15.
    Jeon HJ, et al. (2010) CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. Circulation. 121:1124–33.CrossRefPubMedGoogle Scholar
  16. 16.
    Snell LM, Lin GH, McPherson AJ, Moraes TJ, Watts TH. (2011) T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy. Immunol. Rev. 244:197–217.CrossRefPubMedGoogle Scholar
  17. 17.
    Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. (2010) Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin. Oncol. 37:508–16.CrossRefPubMedGoogle Scholar
  18. 18.
    International HapMap Consortium. (2003) The International HapMap Project. Nature. 426:789–96.CrossRefGoogle Scholar
  19. 19.
    Kwan T, et al. (2008) Genome-wide analysis of transcript isoform variation in humans. Nat. Genet. 40:225–31.CrossRefPubMedGoogle Scholar
  20. 20.
    Baldassarre D, et al. (2012) Measurements of carotid intima-media thickness and of interadventitia common carotid diameter improve prediction of cardiovascular events: results of the IMPROVE (Carotid Intima Media Thickness [IMT] and IMT-Progression as Predictors of Vascular Events in a High Risk European Population) study. J. Am. Coll. Cardiol. 60:1489–99.CrossRefPubMedGoogle Scholar
  21. 21.
    Gertow K, et al. (2012) Identification of the BCAR1-CFDP1-TMEM170A locus as a determinant of carotid intima-media thickness and coronary artery disease risk. Circ. Cardiovasc. Genet. 5:656–65.CrossRefPubMedGoogle Scholar
  22. 22.
    Farrall M, et al. (2006) Genome-wide mapping of susceptibility to coronary artery disease identifies a novel replicated locus on chromosome 17. PLoS. Genet. 2:e72.ai]23._Newton-Cheh C, et al. (2009) Genome-wide association study identifies eight loci associated with blood pressure. Nat. Genet. 41:666–76.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Newton-Cheh C, et al. (2009) Genome-wide association study identifies eight loci associated with blood pressure. Nat. Genet. 41:666–76.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. (2010) MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet. Epidemiol. 34:816–34.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Purcell S, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81:559–75.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Olofsson PS. (2012) Targeting T cell costimulation to prevent atherothrombosis. Circ. Res. 110:800–1.CrossRefPubMedGoogle Scholar
  27. 27.
    Haast RA, Gustafson DR, Kiliaan AJ. (2012) Sex differences in stroke. J. Cereb. Blood Flow Metab. 32:2100–7.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Lawton JS. (2011) Sex and gender differences in coronary artery disease. Semin. Thorac. Cardiovasc. Surg. 23:126–30.CrossRefPubMedGoogle Scholar
  29. 29.
    Malarstig A, et al. (2008) Genetic variants of tumor necrosis factor superfamily, member 4 (TNFSF4), and risk of incident atherothrombosis and venous thromboembolism. Clin. Chem. 54:833–40.CrossRefPubMedGoogle Scholar
  30. 30.
    Kong M, Kim Y, Lee C. (2008) Promoter sequence variants of LIGHT are associated with female vascular dementia. J. Biomed. Sci. 15:545–52.CrossRefPubMedGoogle Scholar
  31. 31.
    Wang X, et al. (2005) Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat. Genet. 37:365–72.CrossRefPubMedGoogle Scholar
  32. 32.
    Olofsson PS, et al. (2009) Genetic variants of TNFSF4 and risk for carotid artery disease and stroke. J. Mol. Med. (Berl). 87:337–46.CrossRefGoogle Scholar
  33. 33.
    VanderLaan PA, Reardon CA, Getz GS. (2004) Site specificity of atherosclerosis: site-selective responses to atherosclerotic modulators. Arterioscler. Thromb. Vasc. Biol. 24:12–22.CrossRefPubMedGoogle Scholar
  34. 34.
    Jashari F, et al. (2013) Coronary and carotid atherosclerosis: Similarities and differences. Atherosclerosis. 227:193–200.CrossRefPubMedGoogle Scholar
  35. 35.
    So T, Lee SW, Croft M. (2008) Immune regulation and control of regulatory T cells by OX40 and 4-1BB. Cytokine Growth Factor Rev. 19:253–62.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    de Boer OJ, van der Meer JJ, Teeling P, van der Loos CM, van der Wal AC. (2007) Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS One. 2:e779.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Ait-Oufella H, et al. (2006) Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med. 12:178–80.CrossRefPubMedGoogle Scholar
  38. 38.
    Hansson GK, Libby P. (2006) The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6:508–19.CrossRefGoogle Scholar
  39. 39.
    Bots ML, Sutton-Tyrrell K. (2012) Lessons from the past and promises for the future for carotid intima-media thickness. J. Am. Coll. Cardiol. 60:1599–604.CrossRefPubMedGoogle Scholar
  40. 40.
    Predazzi IM, et al. (2012) Association between OLR1 K167N SNP and intima media thickness of the common carotid artery in the general population. PLoS One. 7:e31086.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Shah PK. (2010) Screening asymptomatic subjects for subclinical atherosclerosis: can we, does it matter, and should we? J. Am. Coll. Cardiol. 56:98–105.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2014

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Leif Å Söderström
    • 1
    • 2
    • 12
  • Karl Gertow
    • 3
  • Lasse Folkersen
    • 1
    • 4
  • Maria Sabater-Lleal
    • 3
  • Eva Sundman
    • 2
  • Yuri Sheikine
    • 5
  • Anuj Goel
    • 6
  • Damiano Baldassarre
    • 7
    • 8
  • Steve E. Humphries
    • 9
  • Ulf de Faire
    • 10
  • Hugh Watkins
    • 6
  • Elena Tremoli
    • 7
  • Fabrizio Veglia
    • 8
  • Anders Hamsten
    • 3
  • Göran K. Hansson
    • 1
  • Peder S. Olofsson
    • 1
    • 11
  1. 1.Experimental Cardiovascular Research Group, Department of Medicine, Karolinska InstitutetKarolinska University HospitalStockholmSweden
  2. 2.Department of Anesthesiology and Intensive Care Medicine, Karolinska InstitutetKarolinska University HospitalStockholmSweden
  3. 3.Cardiovascular Genetics and Genomics Group, Atherosclerosis Research Unit, Department of Medicine Solna, Karolinska InstitutetKarolinska University Hospital SolnaStockholmSweden
  4. 4.Department of Molecular GeneticsNovo NordiskCopenhagenDenmark
  5. 5.Department of PathologyBeth Israel Deaconess Medical CenterBostonUSA
  6. 6.Radcliffe Department of Medicine and Wellcome Trust Centre for Human GeneticsUniversity of OxfordOxfordUK
  7. 7.Dipartimento di Scienze Farmacologiche e BiomolecolariUniversità di MilanoMilanItaly
  8. 8.Centro Cardiologico MonzinoIRCCSMilanItaly
  9. 9.Cardiovascular Genetics, BHF Laboratories, Rayne BuildingUniversity College LondonLondonUK
  10. 10.Division of Cardiovascular Epidemiology, Institute of Environmental MedicineKarolinska InstitutetStockholmSweden
  11. 11.Laboratory of Biomedical Science, The Feinstein Institute for Medical ResearchNorth Shore-LIJ Health SystemManhassetUSA
  12. 12.CMM L8:03, Karolinska University HospitaStockholmSweden

Personalised recommendations